Details:
Icatibant injection is therapeutically equivalent to Firazyr®, and supplied as a 3 mL prefilled, single-use syringe that is self-administered subcutaneously into the abdominal area.
Lead Product(s): Icatibant Acetate
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 01, 2020
Details:
Bayer presented data comparing the pharmacokinetic profiles of two extended half-life recombinant factor VIII (FVIII) therapies, Jivi® (antihemophilic factor [recombinant] PEGylated-aucl) and Adynovate® in people living with hemophilia A.
Lead Product(s): Antihemophilic factor recombinant PEGylated-aucl
Therapeutic Area: Genetic Disease Product Name: Jivi
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 15, 2020
Details:
First drug product facility in Europe to complement WuXi Biologics’ existing commercial manufacturing capacities. WuXi Biologics will be the back-up manufacturer for Kovaltry™ of Bayer.
Lead Product(s): Koate DVI
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: WuXi Biologics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition January 16, 2020